CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice

Cardiac complications of CDK4/6 inhibitors for breast cancer.

(2020) Samip R. Master   JOURNAL OF CLINICAL ONCOLOGY

Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC).

(2020) Ranju Kunwor et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer

(2020) Hanny Al-Samkari et al.   Journal of Thoracic Oncology

Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients

(2020) Orly Leiva et al.   Cancers

Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors

(2020) Andrew Dunbar et al.   BLOOD

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

(2019) Frits I. Mulder et al.   HAEMATOLOGICA

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

(2019) Seock-Ah Im et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors

(2019) Lorenzo Gervaso et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma

(2019) Ang Li et al.   ANNALS OF HEMATOLOGY

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

(2018) Marc Carrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism

(2018) Sven R. Olson et al.   JAMA Oncology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of CDK4/6 Inhibition in Breast Cancer

(2015) C. G. Murphy et al.   ONCOLOGIST

Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States

(2012) Alok A. Khorana et al.   CANCER

Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials

(2010) Bostjan Seruga et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD